Press Releases For Month: October 2020
US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

Los Angeles, CA.  October 19, 2020 – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.

Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics is becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future. In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.

Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.

Bioelectronics has several key advantages over traditional treatment methods. The primary advantage is that bioelectronics can be used to treat conditions that current drugs or procedures are unable to treat (i.e., spinal-cord injuries, addiction, depression, Parkinson’s, stroke, multiple sclerosis, regaining vision, and more). A second major advantage is the ability to deliver precise treatment. For example, a bioelectronic device is used to treat paralysis from a stroke or brain injury by specifically bridging the damaged site and restoring motor transmission, whereas the pharmaceutical approach of prescribing drugs is diffuse, lacking the necessary precision targeting to be effective. Additionally, almost all drugs have the potential for undesired side effects which can build up to severe problems over the course of treatment. Many drugs are given for continuous use of pills or injections, over months or years, whereas bioelectronic interventions are designed to repair a problem permanently while allowing for periodic non-invasive adjustments made by the user, doctor, or automatically. Bioelectronic devices can also provide precise, localized regulation of misbehaving glands and organs.

Biomedicine is translating new discoveries in science and biological systems into needed medical care and treatment. It utilizes under-recognized electrical and neuro systems and pathways that take advantage of the body’s innate functions.

Robert Goldstein, CEO of US Nuclear, will bring decades of manufacturing, marketing, and leadership experience to help to accelerate Grapheton’s growth into a world leader in bioelectronics technology.

_________________________________________________________

About US Nuclear Corp.

Originally founded as a spin-off of the Manhattan project in 1946, US Nuclear is a premier manufacturer of hazmat detection equipment, including UAV, mounted radiation, and chemical detection platforms. US Nuclear sales both domestically and internationally and customers include government and military agencies, homeland security, scientific and national laboratories, nuclear power plants, nuclear research facilities, universities, hospitals, and many more.

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com

____________________________________________________

Tritium Monitor Market Soars Due To $20+ Billion ITER Fusion Energy Project

Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

Los Angeles, CA.  October 6, 2020 – As the construction of the huge ITER tokamak grows towards completion, the tritium monitoring market is soaring. As the world leader in quality tritium monitoring instrumentation, US Nuclear’s (OTC: UCLE) Overhoff division is poised to capture a large portion of this business.

The ITER fusion project seeks to develop a major new source of electric power to help supply the world’s fast-growing appetite for dependable, 24/7 electric power. Fusion is fueled by tritium and deuterium, which are both isotopes of hydrogen.  Tritium is in short supply and ITER will fully deplete the global inventory. ITER is a $20+ billion international scientific and engineering project jointly funded by the European UnionChinaIndiaJapanRussiaSouth Korea, and the United States.

TRITIUM USAGE

As a fuel source, tritium is required for ITER and for all other fusion energy projects, but it has many other uses as well. Tritium is used as a radioactive tracer in biomedical and academic research, for producing urgently needed medical scanning isotopes Mo-99 and Tc-99m, designing and testing new pharmaceutical drugs, and providing vital lighting for remote airfields, exit signs, and gun sights. Of course, tritium is also essential for maintaining a deteriorating US nuclear weapons stockpile.

TRITIUM SUPPLY

Deuterium can be extracted from seawater relatively easily, but tritium is only produced significantly in nuclear reactors. The current global inventory is only about 20 kilos!  Tritium is in short supply and ITER hopes to draw from the global inventory. Supplies may be insufficient until eventually the fusion reaction is established and hopefully the tritium can be ‘bred’ within ITER.

The Tennessee Valley Authority, Savannah River Site, and others are all gearing up for tritium production and recapitalization, which means that much more tritium monitoring instrumentation is needed right now and going forward. US Nuclear’s Overhoff division is booming with business, with a large backlog of orders and many more in the pipeline. Overhoff customers include DOE national labs, nuclear power plants, pharmaceutical companies, and US/NATO air force and nuclear navies.

_________________________________________________________

About US Nuclear Corp.

Originally founded as a spin-off of the Manhattan project in 1946, US Nuclear is a premier manufacturer of hazmat detection equipment, including UAV, mounted radiation, and chemical detection platforms. US Nuclear sales both domestically and internationally and customers include government and military agencies, homeland security, scientific and national laboratories, nuclear power plants, nuclear research facilities, universities, hospitals, and many more.

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com

____________________________________________________